NRG-LU004 安全性及生物标志物分析:加速或常规分割放疗联合度伐利尤单抗治疗 PD-L1 高表达局部晚期非小细胞肺癌的 I 期试验
NRG-LU004 是一项 I 期试验,纳入 PD-L1>50% 的 II–III 期局部晚期非小细胞肺癌患者,给予度伐利尤单抗联合加速放疗(60 Gy/15 次)或标准放疗(60 Gy/30 次),主要终点为安全性。24 例可评估患者中仅标准放疗组出现 1 例剂量限制性毒性,两种分割方式均安全可行,且发现与免疫相关不良事件相关的潜在生物标志物。
要点
- PD-L1>50% 的局部晚期 NSCLC 患者可安全接受同步度伐利尤单抗联合放疗而不联合化疗。
- 加速放疗 60 Gy/15 次与标准放疗 60 Gy/30 次均观察到可接受的毒性谱。
- 可溶性蛋白质组分析提示标准放疗组免疫变化更显著,并发现免疫相关不良事件的潜在生物标志物。
核心结论
- 在 PD-L1 高表达(>50%)的局部晚期非小细胞肺癌患者中,同步度伐利尤单抗联合标准分割或加速分割胸部放疗而不联合化疗是安全的。
研究设计与样本
- I 期试验(NRG-LU004)纳入 II–III 期、PD-L1>50% 的局部晚期非小细胞肺癌患者,分为加速放疗组(60 Gy/15 次)和标准放疗组(60 Gy/30 次),各 12 例可评估,均含初始队列和扩展队列。
- 患者接受度伐利尤单抗 1500 mg 每 4 周一次共 13 周期,主要终点为剂量限制性毒性评估的安全性,可行性定义为前 8 周内≥80% 患者接受≥80% 计划度伐利尤单抗。
主要发现
- 24 例可评估患者中仅标准放疗组发生 1 例剂量限制性毒性,两个初始队列均推进至扩展队列。
- 83% 患者按方案完成放疗;分析时 24% 患者已完成全部度伐利尤单抗周期。
- 加速放疗组不良事件包括 4 例 3 级、1 例 4 级(淋巴细胞减少)和 1 例 5 级(肺部感染,无关);标准放疗组报告 8 例 3 级和 1 例 5 级(呼吸衰竭,无关)。
- 度伐利尤单抗可行性在加速放疗组为 85%、标准放疗组为 75%;放疗按方案完成率加速放疗组 12/12、标准放疗组 10/12。
- 可溶性蛋白质组分析显示显著免疫变化,尤其在标准放疗组,并发现免疫相关不良事件的潜在生物标志物。
关键数值与推荐
- 安全性主要终点通过剂量限制性毒性评估,可评估患者 24 例(每组 12 例),仅标准放疗组发生 1 例剂量限制性毒性。
- 可行性定义为前 8 周内≥80% 患者接受≥80% 计划度伐利尤单抗,实际可行性加速放疗组 85%、标准放疗组 75%。
临床怎么用
- 对于 PD-L1>50% 的局部晚期非小细胞肺癌患者,可考虑同步度伐利尤单抗联合胸部放疗而不联合化疗的治疗策略。
- 加速放疗(60 Gy/15 次)和标准放疗(60 Gy/30 次)均可作为联合度伐利尤单抗的放疗分割选择,需关注免疫相关不良事件。
局限性
- 样本量小(24 例可评估),分析时仅 24% 患者完成全部度伐利尤单抗周期,随访尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with advanced non-small cell lung cancer (NSCLC) and high programmed death ligand-1 (PD-L1) (>50%) expression show improved outcomes with immune checkpoint inhibitors compared to chemotherapy. We hypothesized that concurrent durvalumab and radiation therapy (RT) without concurrent chemotherapy would be safe and feasible in patients with locally advanced NSCLC (LA-NSCLC). METHODS AND MATERIALS: Stage II to III LA-NSCLC patients with PD-L1 >50% received durvalumab (1500 mg every 4 weeks × 13 cycles) with either accelerated RT (ACRT, 60 Gy/15 fractions) or standard RT (SDRT, 60 Gy/30 fractions), as initial and expansion cohorts. The primary objective was safety, assessed through dose-limiting toxicities. Feasibility was defined as ≥80% of patients receiving ≥80% of planned durvalumab in the first 8 weeks. Peripheral blood specimens were collected at baseline and throughout treatment for exploratory immune profiling analyses to evaluate biomarkers related to treatment and/or adverse events (AEs). RESULTS: Among 24 evaluable patients (n = 12 each), one dose-limiting toxicity occurred (SDRT arm). Both initial cohorts advanced to expansion. Most patients received RT per protocol (83%). At the time of the analysis, 24% had completed all durvalumab cycles. In ACRT, AEs included 4 grade 3, one grade 4 (lymphopenia), and one grade 5 (lung infection, unrelated). In SDRT, there were 8 grade 3 and one grade 5 (respiratory failure, unrelated) events reported. Durvalumab feasibility was 85% in ACRT and 75% in SDRT. RT was completed per protocol in all 12 ACRT and 10 of 12 for SDRT. Soluble proteomic analysis revealed significant immune changes, particularly in the SDRT arm, and potential biomarkers of immune-related AEs. CONCLUSIONS: Chemotherapy-free thoracic RT with either standard fractionated or accelerated courses with concurrent durvalumab is safe in PD-L1 high LA-NSCLC.
引用
- Lin SH, Pugh SL, Valle DMD, et al. Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1-High Locally Advanced Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42731785. doi:10.1016/j.ijrobp.2026.08.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。